Current pharmacotherapy for hepatitis B infection
- 1 August 2001
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 2 (8), 1289-1298
- https://doi.org/10.1517/14656566.2.8.1289
Abstract
Chronic infection with the hepatitis B virus (HBV) affects 350 million people worldwide, or approximately 5% of the global population, and commonly results in cirrhosis and hepatocellular carcinoma. Until recently, the only available treatment was injectable interferon alpha and response rates were suboptimal. Moreover, this expensive and toxic therapy had little applicability in the endemic regions of the world, i.e., Asia and Africa. The realisation that orally available nucleoside and nucleotide agents may effectively control this infection opened a new era in the management of chronic hepatitis B. Oral lamivudine recently became approved for treatment of hepatitis B worldwide. It is free of significant toxicity, improves liver histology and rapidly diminishes HBV DNA levels; lamivudine is expected to become the first-line therapy of choice. Nevertheless, the consistent emergence of lamivudine-resistant variants mandates the need to develop additional therapeutic agents. Adefovir dipivoxil, a nucleotide, and entecavir, a nucleoside agent, are promising new drugs that might eventually be used in combination with lamivudine and therefore reduce the incidence of drug resistance. There is a critical need to advance the research of hepatitis B antiviral agents so that effective combination therapies can become widely available.Keywords
This publication has 46 references indexed in Scilit:
- Impact of Antivirals and Emergence of Drug Resistance: HSV-2 Epidemic ControlAIDS Patient Care and STDs, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfaHepatology, 1997
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Effect of drinking on the outcome of cirrhosis in patients with hepatitis B or CJournal of Gastroenterology and Hepatology, 1992
- Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferonJournal of Hepatology, 1992
- Mechanisms of Action of InterferonsSeminars in Liver Disease, 1989
- Clinical and histological features of delta infection in chronic hepatitis B virus carriers.Journal of Clinical Pathology, 1985
- Effects of short‐term, high‐dose prednisone treatment of patients with HBsAg‐positive chronic active hepatitisLiver International, 1985